🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Cliff Asness’s ANIK Holdings & Trades

First Buy
Q4 2013
Duration Held
44 Quarters
Largest Add
Q3 2014
+116,000 Shares
Current Position
69,280 Shares
$665,781 Value

Cliff Asness's ANIK Position Overview

Cliff Asness (via Aqr Capital Management LLC) currently holds 69,280 shares of Anika Therapeutics, Inc. (ANIK) worth $665,781, representing 0.00% of the portfolio. First purchased in 2013-Q4, this long-term strategic position has been held for 44 quarters.

Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in ANIK, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2014, adding 116,000 shares. Largest reduction occurred in Q3 2024, reducing 76,681 shares.

Analysis based on 13F filings available since 2013 Q2

Cliff Asness's Anika Therapeutics (ANIK) Holding Value Over Time

Track share changes against reported price movement

Quarterly Anika Therapeutics (ANIK) Trades by Cliff Asness

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 +19,817 Add 40.06% 69,280 $9.61
Q3 2025 -1,351 Reduce 2.66% 49,463 $9.40
Q2 2025 +38,757 Add 321.45% 50,814 $10.58
Q1 2025 +12,057 New Buy 12,057 $15.03
Q4 2024 -30,692 Sold Out 0 $0.00
Q3 2024 -76,681 Reduce 71.42% 30,692 $24.70
Q2 2024 +8,072 Add 8.13% 107,373 $25.33
Q1 2024 +5,150 Add 5.47% 99,301 $25.40
Q4 2023 +20,597 Add 28.00% 94,151 $22.66
Q3 2023 +41,479 Add 129.32% 73,554 $18.63
Q2 2023 +251 Add 0.79% 32,075 $25.98
Q1 2023 -17 Reduce 0.05% 31,824 $28.72
Q4 2022 +7,451 Add 30.55% 31,841 $29.60
Q3 2022 +9,685 Add 65.86% 24,390 $23.78
Q2 2022 +14,705 New Buy 14,705 $22.31
Q4 2020 -53,796 Sold Out 0 $0.00
Q3 2020 -63,996 Reduce 54.33% 53,796 $35.39
Q2 2020 -3,655 Reduce 3.01% 117,792 $37.73
Q1 2020 +31,368 Add 34.82% 121,447 $28.91
Q4 2019 +54,668 Add 154.38% 90,079 $51.85
Q3 2019 +29,398 Add 488.91% 35,411 $54.90
Q2 2019 -9,869 Reduce 62.14% 6,013 $40.58
Q1 2019 +775 Add 5.13% 15,882 $30.22
Q4 2018 +177 Add 1.19% 15,107 $33.63
Q3 2018 -14,193 Reduce 48.73% 14,930 $42.13
Q2 2018 -14,253 Reduce 32.86% 29,123 $32.00
Q1 2018 +552 Add 1.29% 43,376 $49.73
Q4 2017 -4,455 Reduce 9.42% 42,824 $53.92
Q3 2017 -5,461 Reduce 10.35% 47,279 $58.00
Q2 2017 -9,600 Reduce 15.40% 52,740 $49.36
Q1 2017 -51,336 Reduce 45.16% 62,340 $43.44
Q4 2016 -34,675 Reduce 23.37% 113,676 $48.96
Q3 2016 +43,754 Add 41.83% 148,351 $47.85
Q2 2016 +48,713 Add 87.17% 104,597 $53.64
Q1 2016 -47,453 Reduce 45.92% 55,884 $44.72
Q4 2015 -17,358 Reduce 14.38% 103,337 $38.16
Q3 2015 -63,619 Reduce 34.52% 120,695 $31.82
Q2 2015 -17,537 Reduce 8.69% 184,314 $33.03
Q1 2015 -22,301 Reduce 9.95% 201,851 $41.17
Q4 2014 +62,529 Add 38.69% 224,152 $40.74
Q3 2014 +116,000 Add 254.26% 161,623 $36.66
Q2 2014 +3,700 Add 8.83% 45,623 $46.34
Q1 2014 +32,600 Add 349.67% 41,923 $41.10
Q4 2013 +9,323 New Buy 9,323 $38.19

Cliff Asness's Anika Therapeutics Investment FAQs

Cliff Asness first purchased Anika Therapeutics, Inc. (ANIK) in Q4 2013, acquiring 9,323 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Cliff Asness has held Anika Therapeutics, Inc. (ANIK) for 44 quarters since Q4 2013.

Cliff Asness's largest addition to Anika Therapeutics, Inc. (ANIK) was in Q3 2014, adding 161,623 shares worth $5.92 M.

According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 69,280 shares of Anika Therapeutics, Inc. (ANIK), valued at approximately $665,781.

As of the Q4 2025 filing, Anika Therapeutics, Inc. (ANIK) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.

Cliff Asness's peak holding in Anika Therapeutics, Inc. (ANIK) was 224,152 shares, as reported at the end of Q4 2014.